A new study shows that a combination of THC and CBD, two compounds from cannabis, dramatically reduced agitation in people with Alzheimer's disease and other forms of dementia. In a rigorous, placebo-controlled trial involving 120 participants, 87% of those who received the cannabis medication saw improvement in agitation symptoms after 12 weeks, compared to just 24% of those who received a placebo.

What Did the Study Find About Cannabis and Dementia Agitation?

Researchers from the Medical University of South Carolina and Georgetown University tested a cannabis preparation called T2:C100, which contained 2 milligrams of THC and 100 milligrams of CBD. The participants were people with dementia who were eligible for hospice care and were experiencing clinically significant agitation. The results were striking: after just two weeks, 84% of participants receiving the cannabis medication showed improvement on a standardized agitation scale, compared to 31% in the placebo group.

The study, called the LIBBY trial (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol), was funded by the National Institutes of Health and the Alzheimer's Association. Participants had an average age of 80.5 years. Lead investigator Jacobo Mintzer emphasized the significance of these findings.

"This is a robustly positive, randomized, controlled trial that represents a major step forward in treatment for a population that has been historically overlooked in clinical research. We now have evidence supporting a new and very effective treatment approach for agitation that may be appropriate for people in the final stages of dementia at the end of life, offering them grace and peace in what is often an extremely difficult time for patients and their families," said Jacobo Mintzer, lead investigator.

Jacobo Mintzer, Lead Investigator, Medical University of South Carolina and Georgetown University

Mintzer also noted that the level of response observed in the trial was unusual. "Rarely do we see close to 90 percent of patients in a trial respond positively to a new medication," he explained.

Why Does This Matter for Dementia Patients and Their Families?

Agitation in late-stage dementia is one of the most challenging symptoms to manage. It manifests as restlessness, aggression, and emotional distress that can profoundly affect both patients and their caregivers. Current treatment options are limited and often come with significant side effects. The cannabis-based approach offers a potential alternative that appears safer and more effective than existing medications.

Brigid Reynolds, a co-principal investigator on the study, emphasized the importance of this finding for patients and families struggling with end-of-life care.

"Proving the clear benefit of THC/CBD over placebo can bring hope to millions of patients, their families, caregivers and loved ones. Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression and emotional distress that can profoundly impact patients and their caregivers. Current treatment options are limited and often carry significant side effects, underscoring the need for safer, more effective therapies," stated Brigid Reynolds.

Brigid Reynolds, Co-Principal Investigator, Georgetown University

How Does This Fit Into Broader Cannabis Research?

This study is not an isolated finding. The American Medical Association adopted a resolution last month recognizing both the risks and potential therapeutic benefits of marijuana use by older adults. The resolution acknowledges that while there is a higher incidence of dementia among individuals who use cannabis, the compound "may offer therapeutic benefits for managing agitation in dementia patients, potentially serving as an alternative to antipsychotic medications".

Previous research has also pointed toward cannabis compounds as potentially beneficial for aging-related conditions. A study published last year found that CBD shows "promising" results in reducing inflammation and cognitive decline associated with aging. Additionally, a 2024 scientific review concluded that THC, CBD, and lesser-known compounds in marijuana are "promising agents in treating neurodegenerative disorders".

What Are the Key Takeaways for Patients and Caregivers?

• Effectiveness Rate: The cannabis preparation reduced agitation in 87% of dementia patients after 12 weeks, compared to 24% in the placebo group, representing a significant difference in outcomes.
• Specific Formulation: The study used a precise combination of 2 milligrams of THC and 100 milligrams of CBD, suggesting that the ratio and dosage matter for therapeutic benefit.
• Potential Alternative: These results suggest cannabis-based treatments may offer a safer option than antipsychotic medications, which often carry serious side effects in older adults.
• End-of-Life Care: The medication appears particularly suited for people in the final stages of dementia who are eligible for hospice care, addressing a population with limited treatment options.

Elizabeth Edgerly, vice president for care and support for the Alzheimer's Association, highlighted the broader significance of the research. "The LiBBY study directly addresses one of the most challenging and under-discussed aspects of Alzheimer's disease, end-of-life agitation," she noted. "These results not only highlight a promising therapeutic option, but also underscore the importance of prioritizing attention, care and research for individuals in mid- and late-stage Alzheimer's and related dementias".

While these results are encouraging, it's important to note that this was a single study, albeit a well-designed one. Further research will be needed to confirm these findings, understand long-term effects, and determine how this treatment might be integrated into standard dementia care. Patients and families interested in this approach should discuss it with their healthcare providers, particularly those caring for someone in the late stages of dementia.